210 related articles for article (PubMed ID: 16163243)
1. False elevations in prostate-specific antigen levels affecting patient management.
Kummar S; Shafi NQ
Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
[No Abstract] [Full Text] [Related]
2. Benign positive margins after radical prostatectomy means a poor prognosis--con.
Rubin MA; Montie JE
Urology; 2005 Feb; 65(2):221-3. PubMed ID: 15708026
[No Abstract] [Full Text] [Related]
3. Benign positive margins after radical prostatectomy means a poor prognosis--pro.
Djavan B; Milani S; Fong YK
Urology; 2005 Feb; 65(2):218-20. PubMed ID: 15708025
[No Abstract] [Full Text] [Related]
4. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
5. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies.
Park S; Wians FH; Cadeddu JA
Int J Urol; 2007 Mar; 14(3):251-3. PubMed ID: 17430267
[TBL] [Abstract][Full Text] [Related]
6. Avoidance and management of positive surgical margins before, during and after radical prostatectomy.
Bott SR; Kirby RS
Prostate Cancer Prostatic Dis; 2002; 5(4):252-63. PubMed ID: 12627209
[TBL] [Abstract][Full Text] [Related]
7. Biochemical remission after resection of prostate cancer lung metastasis.
Chao DH; Higgins JP; Brooks JD
Urology; 2004 Mar; 63(3):584-5. PubMed ID: 15028469
[TBL] [Abstract][Full Text] [Related]
8. Artificial prostate-specific antigen persistence after radical prostatectomy.
Poyet C; Hof D; Sulser T; Müntener M
J Clin Oncol; 2012 Feb; 30(5):e62-3. PubMed ID: 22203757
[No Abstract] [Full Text] [Related]
9. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
10. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for locally recurrent prostate cancer.
Kirkpatrick JP; Anscher MS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):933-42. PubMed ID: 16555435
[TBL] [Abstract][Full Text] [Related]
12. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
Levinson A; Nagler EA; Lowe FC
Urology; 2005 Jan; 65(1):91-4. PubMed ID: 15667871
[TBL] [Abstract][Full Text] [Related]
13. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer.
Morgan BR; Tarter TH
J Urol; 2001 Dec; 166(6):2311-2. PubMed ID: 11696766
[TBL] [Abstract][Full Text] [Related]
14. The value of prostate-specific antigen in the management of localized prostatic cancer.
Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
16. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy can wait in PSA-only relapse.
Schmidt C
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122737
[No Abstract] [Full Text] [Related]
19. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
20. The surgical learning curve for prostate cancer control after radical prostatectomy.
Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
